Abstract:Objective: Cancer-associated cachexia is a devastating pathological disorder characterized by skeletal muscle wasting and fat storage depletion. Circular RNA, a newly discovered class of noncoding RNAs with important roles in regulating lipid metabolism, has not been fully understood in the pathology of cachexia. We aimed to identify circular RNAs that are upregulated in adipose tissues from cachectic patients and explore their function and mechanism in lipid metabolism. Methods: Whole transcriptome RNA sequencing was used to screen for differentially expressed circRNAs. Quantitative reverse transcription PCR was applied to detect the expression level of circPTK2 in adipose tissues. The diagnostic value of circPTK2 was evaluated in adipose tissues from patients with and without cachexia. Then, function experiments in vitro and in vivo were performed to evaluate the effects of circPTK2 on lipolysis and adipogenesis. Mechanistically, luciferase reporter assay, RNA immunoprecipitation, and fluorescent in situ hybridization were performed to confirm the interaction between circPTK2 and miR-182-5p in adipocytes. Results: We detected 66 differentially expressed circular RNA candidates and proved that circPTK2 was upregulated in adipose tissues from cachectic patients. Then we identified that circPTK2 was closely related to the pathological process of cachexia and could be used as a diagnostic marker. Mechanistically, circPTK2 bound competitively to miR-182-5p and abrogated the suppression on its target gene JAZF1, which finally led to promotion of lipolysis and inhibition of adipogenesis. In vivo experiments demonstrated that overexpression of circPTK2 inhibited adipogenesis and enhanced lipolysis. Conclusions: Our findings reveal the novel role of circPTK2 in promoting lipolysis and reducing adipogenesis via a ceRNA mechanism and provide a potential diagnostic biomarker and therapeutic target for cancer-associated cachexia. (c) 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The Role of Non-Coding RNAs in Regulating Cachexia Muscle Atrophy

Novel Noncoding RNA CircPTK2 Regulates Lipolysis and Adipogenesis in Cachexia

The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis

An Analysis of Differentially Expressed Coding and Long Non-Coding RNAs in Multiple Models of Skeletal Muscle Atrophy

Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)

The role of non-coding RNAs in muscle aging: regulatory mechanisms and therapeutic potential

The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia

Inhibition of Lncrna MAAT Controls Multiple Types of Muscle Atrophy by Cis- and Trans-Regulatory Actions

Targeting cancer cachexia: Molecular mechanisms and clinical study

Molecular Mechanisms of Cachexia: A Review

Targeting MuRF1 to Combat Skeletal Muscle Wasting in Cardiac Cachexia: Mechanisms and Therapeutic Prospects

Regulatory Role of MicroRNAs in Muscle Atrophy During Exercise Intervention

Muscle atrophy‐related myotube‐derived exosomal microRNA in neuronal dysfunction: Targeting both coding and long noncoding RNAs

The Role of non-coding RNAs in colorectal cancer, with a focus on its autophagy

Identification and functional analysis of a potential key lncRNA involved in fat loss of cancer cachexia

Molecular mechanisms of cancer cachexia. Role of exercise training

Regulatory mechanisms of autophagy-related ncRNAs in bone metabolic diseases

Transcriptomic signature of cancer cachexia by integration of machine learning, literature mining and meta-analysis

Stage-specific Muscle Wasting Mechanisms in a Novel Cancer Cachexia Mouse Model for Ovarian Granulosa Cell Tumor

Cancer Cachexia: Molecular Mechanism and Pharmacological Management